FAP-2286 (177Lu / 68Ga)
A FAP-targeted theranostic pair: one version images almost any solid tumour, the other treats it with radiation.
Overview
FAP-2286 is a theranostic pair: a cyclic peptide that binds fibroblast activation protein (FAP), linked to a DOTA chelator carrying 68Ga for PET imaging or 177Lu for beta therapy. FAP sits on cancer-associated fibroblasts in the stroma of most solid tumours rather than on cancer cells, so one agent can image and irradiate many tumour types, and the cyclic peptide gives longer tumour retention than the FAPI small molecules used for imaging. Clovis Oncology developed it until its 2022 bankruptcy; Novartis then acquired it via 3B Pharmaceuticals. The 177Lu-FAP-2286 LuMIERE phase 1/2 trial is dose-escalating in cycles every 6 weeks with pancreatic, sarcoma and breast cohorts. For a newcomer: a radioligand aimed at the scaffolding around tumours rather than the tumour cells.
- Detector ring
- FAP on fibroblasts
- 511 keV photon pair
Cyclic peptide FAP binder with DOTA chelator for 68Ga (imaging) or 177Lu (therapy). Connects to FAP.
- PSMA / SSTR-positive cell
1.Radioligand circulates and binds FAP on cancer-associated fibroblasts on tumour cells
- Route
- IV infusion (177Lu) or injection (68Ga)
- Schedule
- LuMIERE phase 1/2 dose escalation, cycles every 6 weeks
- Monitoring
- Blood counts, renal function
Source: clinicaltrials.gov/study/NCT04939610. Doses are for orientation; the current label governs.
- Jan 2023Filing / dealUS
Novartis acquires rights after Clovis bankruptcy source
| Adverse event |
|---|
| Anaemia |
| Thrombocytopenia |
| Fatigue |
| Nausea |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"FAP-2286" OR ABSTRACT:"FAP-2286" OR TITLE:"177Lu / 68Ga" OR ABSTRACT:"177Lu / 68Ga") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FAP-2286 (177Lu / 68Ga), not a curated reading list.
Similar pages
not linked directly; found by shared links- IdeaA university cyclotron network with shared regulatory files for new tracers
Shares FAP theranostics as a pan-cancer stromal strategy, Uwe Haberkorn, FAPI PET, Radiopharmaceutical roadmap: iodine → lutetium → actinium.
- AgentGallium-68 FAPI-46
Shares FAP imaging to stop futile pancreatic surgery, FAP, FAPI PET, Gallium-68.
- PersonFrederik Giesel
Shares University Hospital Düsseldorf / CIO Düsseldorf, FAP, FAPI PET, Gallium-68.
- IndicationPancreatic ductal adenocarcinoma
Shares FAP imaging to stop futile pancreatic surgery, FAP, FAPI PET.
- InstitutionHeidelberg University Hospital / NCT / DKFZ
Shares University Hospital Düsseldorf / CIO Düsseldorf, Uwe Haberkorn, FAP, FAPI PET.
- CompanyAdvanced Accelerator Applications (Novartis)
Shares A Study of 177Lu-FAP-2286 in Advanced Solid Tumors, Novartis, Gallium-68, Radioligand therapy (beta emitters).
- PersonKen Herrmann
Shares FAP, FAPI PET, Radioligand therapy (beta emitters), Lutetium-177.
- TrialStudy of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Shares Novartis, Gallium-68, Lutetium-177.